System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 9 citations

PubMed: 37457699 DOI: 10.3389/fimmu.2023.1213716

Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.

Front Immunol 14:1213716

Authors: Chunmei Hu, Min Liu, Yutao Li, Yi Zhao, Amit Sharma, Haotian Liu, Ingo G H Schmidt-Wolf

Affiliations

  • Department of Otolaryngology-Head and Neck Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • Department of Otolaryngology-Head and Neck Surgery, West China Hospital of Sichuan University, Chengdu, China.
  • Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
  • Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.

Abstract

Head and neck cancer (HNC) ranks as the sixth most prevalent type of cancer globally and accounts for about 4% of all types of cancer. Among all HNC, most are head and neck squamous cell carcinoma (HNSCC) with clinical therapies that include surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, and multimodal treatments. In recent years, chimeric antigen receptor (CAR)-T cell immunotherapy has significantly transformed the therapeutic approaches for leukemia and lymphoma and has garnered increased attention as a potential treatment for a wide range of cancers. However, CAR-T immunotherapy in solid tumors, especially HNSCCs, lags significantly behind due to the paucity of tumor-specific antigens, high levels of tumor heterogeneity, immunosuppressive tumor microenvironment, the risk of treatment-related toxicities and off-target adverse events in HNSCCs. The objective of this review is to explore the advancement of CAR-T cell therapy in the treatment of HNSCCs. We aim to outline the targeted antigens in HNSCCs, highlight the challenges and potential solutions, and discuss the relevant combination therapies. Our review presents a comprehensive overview of the recent developments in CAR-T cell therapy for HNSCCs, and provides valuable insights into future research avenues.

MeSH

Cells, Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors, Squamous Cell Carcinoma Of Head And Neck, Immune System Diseases, Head And Neck Neoplasms, Therapeutics, T-Lymphocytes, Car-T Cell

Cited by